Drug Patent Watch

OCTOBER 28, 2024

The pharmaceutical industry relies heavily on Contract Development and Manufacturing Organizations (CDMOs) to streamline the drug development and manufacturing process. CDMOs provide a wide range of services that cater to the diverse needs of pharmaceutical companies, from early-stage development to commercial manufacturing.

Pharmaceutical Companies

Drug Target Review

JULY 3, 2025

It is becoming increasingly evident that generative artificial intelligence (GenAI) is a resourceful tool for helping pharmaceutical companies reduce manual tasks required by clinical trials.

Drug Development

Drug Target Review

DECEMBER 11, 2024

For small- and medium-sized pharmaceutical companies, outsourcing represents a strategic leap forward, offering a gateway to unparalleled expertise and cutting-edge analytical technologies. Such an approach ensures reliable preclinical toxicology data and supports the transition of innovative therapies from the lab to clinical trials.

International

Drug Target Review

JULY 21, 2025

Prior to WuXi AppTec, Dr Li held scientific leadership roles in CROs and pharmaceutical companies in Canada and Japan. Her expertise spans CRO oversight, regulatory strategy and CTD-compliant submissions for INDs and NDAs. She holds a PhD in pharmacology from Japan, and an MD and MSc from China.

Drug Development

FDA Law Blog: Biosimilars

MARCH 18, 2025

Specifically, the Court focused on the purpose: to compensate pharmaceutical companies for the effective truncation of their patent terms while waiting for regulatory approval of new drug applications. The Court thus explained that interpreting the patent in 35 U.S.C.

Pharmaceutical Companies

Alta Sciences

JUNE 6, 2025

For biotechnology and pharmaceutical companies, automation can decrease their drug-to-market development time and remain financially competitive in an evolving market. My experience as an optimization scientist has shown how automation can be a valuable tool to support drug development for sponsors of all sizes.

Pharmacokinetics

The Pharma Data

JUNE 18, 2025

Backed by two leading pharmaceutical companies, Daiichi Sankyo and Merck, the study aims to validate ifinatamab deruxtecan as a new treatmen 100 49702 0 49702 0 0 110k 0 --:--:-- --:--:-- --:--:-- 110kt option for patients with advanced prostate cancer who have progressed beyond hormone therapy.

Trials

Drug Patent Watch

DECEMBER 9, 2024

This includes: Preclinical studies Clinical trials Regulatory approval Manufacturing and marketing Throughout this process, pharmaceutical companies seek to protect their investments through patents.

Drugs

The Pharma Data

JUNE 25, 2025

Novartis Finalizes Acquisition of Regulus Therapeutics, Strengthening Its Renal Disease Portfolio with Promising ADPKD Therapy Novartis AG, a leading global pharmaceutical company, has officially completed its acquisition of Regulus Therapeutics Inc. , a biotechnology firm known for its expertise in microRNA-targeting therapies.

RNA

PPD

NOVEMBER 11, 2024

By accelerating timelines, anticipating challenges and alleviating bottlenecks, pharmaceutical companies and combined CDMO and CRO partners together can help ensure those potential treatments reach the patients who need them as efficiently as possible.

Drug Development

The Pharma Data

JUNE 13, 2025

This includes assistance in intellectual property strategy, securing funding, developing business plans, and preparing for eventual collaboration with large pharmaceutical companies or investors. The main objective of MEDISO is to aid Japanese drug-discovery ventures in navigating the complex path toward commercial readiness.

Research

DrugBank

JUNE 18, 2025

This means pharmaceutical companies must remain vigilant and adaptable to comply with evolving regulations. Regulatory agencies require pharmaceutical companies to submit preclinical and clinical trial data covering toxicology, pharmacokinetics, pharmacodynamics, and long-term safety monitoring.

Drug Development

Alta Sciences

JULY 3, 2025

It was the perfect venue for meaningful conversations with pharmaceutical companies, fellow CROs, and academic experts, all eager to explore the latest breakthroughs in drug development. BIG IDEAS AND BRIGHT CONVERSATIONS ABOUT DRUG DEVELOPMENT The CPHI Innovation Theater was buzzing with energy—and Altasciences was right in the mix.

Small Molecule

SugarCone Biotech

JUNE 27, 2025

Finally, while there are clear front runners among the pharmaceutical companies developing targeted therapeutics for these antigens there are also emerging biotechs aggressively pursuing these targets. Each target and each therapeutic modality induces varying degrees of clinical efficacy, as well as causing toxicities.

Therapies

SugarCone Biotech

JUNE 19, 2025

Finally, while there are clear front runners among the pharmaceutical companies developing targeted therapeutics for these antigens there are also emerging biotechs aggressively pursuing these targets. Each target and each therapeutic modality induce varying degrees of clinical efficacy, as well as causing toxicities.

Therapies

The Pharma Data

JUNE 24, 2025

We are proud that our partnership with Tsinghua University has set a benchmark for scientific research collaboration between multinational pharmaceutical companies and high-profile academic institutions in China. “This progress is driven by the dedicated efforts and strong collaborations among innovators of science and business.

Pharma R&D

Drug Patent Watch

JULY 15, 2025

Read on to learn how MRAs are changing the game for generic drug approvals and what this means for patients, pharmaceutical companies, and regulatory bodies alike: [link] #MRAs #GenericDrugs #RegulatoryReform" But what exactly are MRAs, and how can they be leveraged to drive innovation and access to life-saving treatments?

Pharmaceutical Companies

Drug Target Review

JULY 14, 2025

Ignota Labs specialises in identifying failed drug candidates, resolving their issues and turning them around before selling them back to pharmaceutical companies. ” Meet the interviewee Dr Layla Hosseini-Gerami bridges the worlds of chemistry, biology and AI in her role as Chief Data Science Officer at Ignota Labs.

Drugs

Drug Target Review

JUNE 18, 2025

For companies hoping to beat those odds, Nick says it comes down to two things: sharing risk early and being willing to walk away sooner. “If The companies that survive are not necessarily the ones with the deepest pockets. If you can upfront figure out if this could work – and say no faster – that helps everyone.”

Drugs

Drug Target Review

MARCH 4, 2025

The MyPhenome test has already gained traction among obesity specialists, particularly in Chicago and Florida, and Phenomix has formed strategic partnerships with multiple pharmaceutical companies to support clinical trials and further analyse obesity-related data.

Therapies

Drug Patent Watch

MAY 19, 2025

From predicting market trends to identifying potential blockbusters, AI is revolutionizing the way pharmaceutical companies approach portfolio optimization. Want to learn more about how AI-powered portfolio management can take your pharmaceutical business to the next level?

Pharmaceuticals

Drug Target Review

JUNE 2, 2025

With a deep understanding of the industry’s complexities and the evolving market needs, he has been instrumental in providing innovative solutions for both biotech startups and large pharmaceutical companies.

Small Molecule

thought leadership

FEBRUARY 10, 2025

For pharmaceutical companies, this shift presents both challenges and opportunities. In today's digital age, social media has transformed how businesses communicate with their audiences. Social media can significantly enhance brand visibility and patient engagement and have an impact on the overall healthcare sector.

Pharmaceutical Companies

Drug Target Review

MARCH 3, 2025

However, promising pilot data from ongoing collaborations with pharmaceutical companies suggest that brain organoids are set to become a valuable tool in preclinical research. . “There’s still a long way to go to convince pharma that this model is really useful,” he acknowledges.

Disease

Codon

NOVEMBER 3, 2024

Based on these results, Waksman asked the pharmaceutical company Merck to mass-produce streptomycin for further tests that could provide clearer evidence of its efficacy and safety. The drug didn’t cure the animals at such low doses, but their health did improve, hinting at the drug’s efficacy.

Vaccine

Drug Target Review

JUNE 14, 2025

I began developing my own scripts to streamline processes, which led me into scientific informatics, where I worked with pharmaceutical companies on cheminformatics. I began in bioinformatics, conducting lab-based genomics work but soon felt the need to dive deeper into the computational side.

Laboratories

Drug Patent Watch

FEBRUARY 27, 2025

This is a nightmare scenario for any pharmaceutical company, and it's a reality that many face every day. Imagine investing years of research and development into a groundbreaking new medication, only to see it copied and sold in foreign markets without your permission. But what can you do to protect your drug patent in global markets?

Marketing

Drug Patent Watch

JUNE 9, 2025

"Navigating the Maze of Regulations: How Pharmaceutical Companies Can Safeguard Their Drug Portfolios As the pharmaceutical industry continues to evolve, regulatory environments are becoming increasingly complex.

Pharmaceutical Companies

Drug Patent Watch

DECEMBER 17, 2024

The Evolving Role of CDMOs in the Pharmaceutical Industry Gone are the days when CDMOs were mere service providers. Today, they’re strategic partners in drug development and manufacturing, offering end-to-end solutions that can make or break a pharmaceutical company’s success.

Pharmaceuticals

BioPharma Drive: Drug Pricing

JUNE 11, 2025

Published June 11, 2025 Ben Fidler Senior Editor post share post print email license The FDA on June 11, 2025 approved Nuvation's Ibtrozi for ROS1-positive non-small cell lung cancer.

FDA

SugarCone Biotech

JULY 6, 2025

Finally, while there are clear front runners among the pharmaceutical companies developing targeted therapeutics for these antigens there are also emerging biotechs aggressively pursuing these targets. Each target and each therapeutic modality induces varying degrees of clinical efficacy, as well as causing toxicities.

Drug Development

ACTO

DECEMBER 17, 2024

Yet, the critical question remains: How can pharmaceutical companies ensure responsible and compliant AI implementation while maximizing its potential for field teams? In addition, 33% of them are currently piloting different solutions in sales, and 44% plan to adopt AI in sales in the next 24 months.

Government

The Pharma Data

JULY 3, 2025

NASDAQ: SBFM), a pharmaceutical company focused on developing and commercializing life-saving medicines across oncology, antiviral therapies, and other therapeutic areas, has announced the commercial launch of its first biosimilar drug, NIOPEG® , in Canada.

Marketing

The Pharma Data

JUNE 20, 2025

Collaborative Development with Orion Corporation Darolutamide was co-developed by Bayer and Orion Corporation, a globally operating Finnish pharmaceutical company with a strong focus on oncology and urology.

Trials

Drug Patent Watch

JANUARY 14, 2025

Key Stakeholders in Pharmaceutical Negotiations Successful negotiations in the pharmaceutical industry require a deep understanding of the various stakeholders involved. These may include: Pharmaceutical companies (big pharma and biotech firms) Contract research organizations (CROs) Regulatory bodies (e.g.,

Pharmaceuticals

Drug Patent Watch

FEBRUARY 13, 2025

They might involve collaborations between pharmaceutical companies, research institutions, and regulatory agencies. But the truth is, partnerships are the backbone of generic drug development, and their impact cannot be overstated. When it comes to developing generic drugs, partnerships can take many forms.

Drug Development

The Premier Consulting Blog

DECEMBER 16, 2024

Pharmaceutical companies may, at times, find themselves at an impasse during development, facing weighty decisions about whether to slow down or hit the brakes on a development program. These decisions are complex, multi-dimensional, and can have significant impact on the future of the company.

Pharmacokinetics